The Maxwell Group

Maxwell Biosciences is a preclinical-stage biotechnology company developing a novel class of synthetic compounds called "Claromers." These small-molecule peptoids are designed to mimic the structure and broad-spectrum activity of human innate immune peptides, such as cathelicidins. The company's Claromer platform produces biomimetic polymers that target and disrupt the membranes of a wide range of pathogens, including viruses, bacteria, and fungi, while remaining non-toxic to healthy human cells. Maxwell's lead programs are focused on difficult-to-treat infectious diseases, including chronic rhinosinusitis and viral pathogens like SARS-CoV-2 and Influenza.